Combination therapy for type 2 diabetes: What are the potential health and cost implications in Canada?

Canadian Journal of Diabetes

Volumn 27, Issue 1, 2003, Pages 33-41

  Caro, J Jaime ^a,b   Salas, Maribel ^a   Ward, Alexandra J ^a   Raggio, Gabriel ^a   O'Brien, Judith A ^a   Grüger, Jens ^c  

^a CARO RESEARCH INSTITUTE   (United States)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; NATEGLINIDE;

ARTICLE; CANADA; COHORT ANALYSIS; CONFIDENCE INTERVAL; COST; COST EFFECTIVENESS ANALYSIS; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; ECONOMIC ASPECT; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; SURVIVAL;

EID: 0041969728     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Tan M-H, MacLean DR. Epidemiology of diabetes mellitus in Canada. Clin Invest Med. 1995;18:240-246.
2. Meltzer S, Leiter L, Daneman D, et al. 1998 clinical practice guidelines for the management of diabetes in Canada. CMAJ. 1998;159(suppl 8):S1-S29.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
5. Mauvais-Jarvis F, Andreelli F, Hanaire-Broutin H, et al. Therapeutic perspectives for type 2 diabetes mellitus: molecular and clinical insights. Diabetes Metab. 2001;27:415-423.
6. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281-303.
7. U.K. Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249-1258.
8. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124:136-145.
9. DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:541-549.
10. Riddle M. Combining sulfonylureas and other oral agents. Am J Med. 2000;108(suppl 6a):S15-S22.
11. Riddle M. Introduction. Am J Med. 2000;108(suppl 6a):S1.
12. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab. 1991;73:1294-1301.
13. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:550-554.
14. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1996;81:4059-4067.
15. Lebovitz HE, Feinglos MN. Sulfonylurea drugs: mechanism of antidiabetic action and therapeutic usefulness. Diabetes Care. 1978;1:189-198.
16. Raptis SA, Dimitriadis GD. Oral hypoglycemic agents: insulin secretagogues, α-glucosidase inhibitors and insulin sensitizers. Exp Clin Endocrinol Diabetes. 2001;109(suppl 2):S265-S287.
17. Olsson J, Lindberg G, Gottsäter M, et al. Increased mortality in type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia. 2000;43:558-560.
18. Hanefeld M, Bouter KP, Dickinson S, Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care. 2000;23:202-207.
19. Hirschberg Y, Karara AH, Pietri AO, McLeod JF. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin. Diabetes Care. 2000;23:349-353.
20. Gribble FM, Manley SE, Levy JC. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166). Diabetes Care. 2001;24:1221-1225.
21. Hollander PA, Schwartz SL, Gatlin MR, et al. Importance of early insulin secretion. Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care. 2001;24:983-988.
22. Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 2000;23:1660-1665.
23. Caro JJ, Klittich WS, Raggio G, et al. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes. Clin Ther. 2000;22:116-127.
24. Caro JJ, Ward AJ, O'Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care. 2002;25:476-481.
25. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care. 1997;20:725-734.
26. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care. 1997;20:735-744.
27. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med. 1993;328:1676-1685.
28. Ballard DJ, Melton LJ 3rd, Dwyer MS, et al. Risk factors for diabetic retinopathy: a population-based study in Rochester, Minnesota. Diabetes Care. 1986;9:334-342.
29. Humphrey LL, Palumbo PJ, Butters MA, et al. The contribution of non-insulin-dependent diabetes to lower-extremity amputation in the community. Arch Intern Med. 1994;154:885-892.
30. Klein R, Klein BE, Moss SE. The Wisconsin epidemiological study of diabetic retinopathy: a review. Diabetes Metab Rev. 1989;5:559-570.
31. Eastman RC, Siebert CW, Harris M, Gorden P. Clinical review 51: implications of the Diabetes Control and Complications Trial. J Clin Endocrinol Metab. 1993;77:1105-1107.
32. Turner RC, Cull CA, Frighi V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-2012.
33. Niranjan V, McBrayer DG, Ramirez LC, et al. Glycemic control and cardiopulmonary function in patients with insulin-dependent diabetes mellitus. Am J Med. 1997;103:504-513.
34. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356-360.
35. Neil A, Hawkins M, Potok M, et al. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care. 1993;16:996-1003.
36. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care. 1998;21:1236-1239.
37. The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;354:617-621.
38. DECODE Study Group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397-404.
39. Glick H. The potential for CVD prevention by reducing post-prandial hyperglycemia. Presented at: Postprandial hyperglycemia - Epidemiology and Control Pathophysiology of Postprandial Hyperglycemia Symposium, International Diabetes Epidemiology Group Satellite Symposium, XVII Congress of the International Diabetes Federation; November 2, 2000; Acapulco, Mexico.
40. Cowie CC, Harris MI. Physical and metabolic characteristics of persons with diabetes. In: Diabetes in America. 2nd ed. Bethesda, MD: National Diabetes Data Group, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 1995:117-164. NIH Publication No. 95-1468.
41. Fujimoto WY. Diabetes in Asian and Pacific Islander Americans. In: Diabetes in America. 2nd ed. Bethesda, MD: National Diabetes Data Group, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 1995:661-682. NIH Publication No. 95-1468.
42. Rewers M, Hamman RF. Risk factors for non-insulin-dependent diabetes. In: Diabetes in America. 2nd ed, Bethesda, MD: National Diabetes Data Group, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 1995:179-220. NIH Publication No. 95-1468.
43. O'Brien JA, Patrick AR, Caro J. Direct medical costs of complications resulting from type 2 diabetes in Canada. BMC Health Serv Res. 2003. In press.
44. Ontario Case Costing Initiative (OCCI). Ontario Case Costing Initiative Database, 1994-1995.
45. The Ontario Case Costing Initiative (OCCI). Ontario Case Costing Initiative Database, 1995-1996.
46. Ontario Ministry of Health and Long-Term Care. Ontario Schedule of Benefits for Physician Services. Toronto, ON: Ontario Ministry of Health and Long-Term Care; 2000.
47. Ontario Ministry of Health and Long-Term Care. Ontario Schedule of Benefits for Laboratory Services. Toronto, ON: Ontario Ministry of Health and Long-Term Care; 1999. Available at: http://www.gov.on.ca/MOH/english/program/ohip/sob/lab/lab-mn.html. Accessed January 18, 2003.
48. Ontario Ministry of Health and Long-Term Care. Ontario Drug Benefit Formularyl Comparative Drug Index. No. 37. Toronto, ON: Ontario Ministry of Health and Long-Term Care; 2001. Available at http://www.gov.on.ca/MOH/english/program/drugs/odbf/odbf_mn.html. Accessed January 18, 2003.
49. O'Brien JA, Caro I, Getsios D, Caro JJ. Diabetes in Canada: direct medical costs of major macrovascular complications. Value Health. 2001;4:258-265.
50. Wake N, Hisashige A, Katayama T, et al. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes Res Clin Pract. 2000;48:201-210.
51. Gray A, Raikou M, McGuire A, et al, on behalf of the United Kingdom Prospective Diabetes Study Group. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ. 2000;320:1373-1378.
52. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296:716-721.
53. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 2000;23(suppl 1):527-531.
54. The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group. Consequences of the new diagnostic criteria for diabetes in older men and women. The DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe). Diabetes Care. 1999;22:1667-1671.
55. Stamler R, Stamler J, Lindberg HA, et al. Asymptomatic hyperglycemia and coronary heart disease in middle-aged men in two employed populations in Chicago. J Chronic Dis. 1979;32:805-815.
56. Fuller JH, Shipley MJ, Rose G, et al. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall Study. Lancet. 1980;1:1373-1376.
57. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes. 1987;36:689-692.
58. Centers for Disease Control and Prevention. Diabetes Surveillance, 1997. Atlanta, GA: U.S. Department of Health and Human Services; 1997.
59. Harris MI. Summary. In: Diabetes in America. 2nd ed. Bethesda, MD: National Diabetes Data Group, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 1995:1-14. NIH Publication No. 95-1468.
60. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146:473-481.
61. Laupacis A, Feeny D, Detsky AS, Tugwell PX. Tentative guidelines for using clinical and economic evaluations revisited. CMAJ. 1993;148:927-929.